Top

14-04-2016 | Staging | Book chapter | Article

Diagnosis and Management of Hereditary Renal Cell Cancer

Authors: Fred H. Menko, Eamonn R. Maher

Publisher: Springer International Publishing

Abstract

Renal cell cancer (RCC) is the common denominator for a heterogeneous group of diseases. The subclassification of these tumours is based on histological type and molecular pathogenesis. Insight into molecular pathogenesis has led to the development of targeted systemic therapies. Genetic susceptibility is the principal cause of RCC in about 2–4 % of cases. Hereditary RCC is the umbrella term for about a dozen different conditions, the most frequent of which is von Hippel–Lindau disease. Here, we describe the main hereditary RCC syndromes, consider criteria for referral of RCC patients for clinical genetic assessment and discuss management options for patients with hereditary RCC and their at-risk relatives.

Alam NA, Barclay E, Rowan AJ et al (2005) Clinical features of multiple cutaneous and uterine leiomyomatosis. An underdiagnosed tumor syndrome. Arch Dermatol 141:199–206PubMed

Albiges L, Guegan J, Le Formal A et al (2014) MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 20:3411–3421CrossRefPubMed

Bardella C, El-Bahrawy M, Frizzell N et al (2011) Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 225:4–11

Barrisford GW, Singer EA, Rosner IL et al (2011) Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol ID 658767

Bausch B, Jilg C, Gläsker S et al (2013) Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol 9:529–538

Benusiglio PR, Gad S, Massard C et al (2014) Case report: Expanding the tumour spectrum associated with the Birt-Hogg-Dubé cancer susceptibility syndrome. F1000Res 3:159

Birt AR, Hogg GR, Dubé WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674–1677CrossRefPubMed

Bratslavsky G, Sudarshan S, Neckers L et al (2007) Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 13:4667–4671CrossRefPubMed

Bricaire L, Odou M-F, Cardot-Bauters C et al (2013) Frequent large germline HRPT2 deletions in a French national cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:E403–E408CrossRefPubMed

Bubien V, Bonnet F, Brouste V et al (2013) High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 50:255–263CrossRefPubMed

Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680CrossRefPubMed

Castro-Vega LJ, Buffet A, De Cubas AA et al (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23:2440–2446CrossRefPubMed

Chow W-H, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7:245–257CrossRefPubMedPubMedCentral

Clague J, Lin J, Cassidy A et al (2009) Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 18:801–807CrossRefPubMedPubMedCentral

Clark GR, Sciacovelli M, Gaude E et al (2014) Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab 99:E2046–E2050CrossRefPubMed

Cohen AJ, Li FP, Berg S et al (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592–595CrossRefPubMed

Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–1356CrossRefPubMed

Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657–668CrossRefPubMed

Daniels MS, Rich T, Weissman S et al (2012) Lifetime cancer risks of PTEN mutation carriers. Clin Cancer Res 18:4213CrossRefPubMed

Delahunt B, Eble N (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544PubMed

Domchek SM, Bradbury A, Garber JE et al (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267–1270CrossRefPubMed

Eble JN, Sauter G, Epstein JI et al (2004) Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours, IARC Press, Lyon

Evenepoel L, Papathomas TG, Krol N et al (2015) Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med 17:610–620

Farley MN, Schmidt LS, Mester JL et al (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11:1061–1071CrossRefPubMedPubMedCentral

Fay AP, Signoretti S, Choueiri TK (2014) MET as a target in papillary renal cell carcinoma. Clin Cancer Res 20:3361–3363CrossRefPubMed

Frank I, Blute ML, Cheville JC et al (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170:2217–2220CrossRefPubMed

Gardie B, Remenieras A, Kattygnarath D et al (2011) Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet 48:226–234CrossRefPubMed

Gill IS, Aron M, Gervais DA et al (2010) Small renal mass. N Engl J Med 362:624–634CrossRefPubMed

Gill AJ, Pachter NS, Clarkson A et al (2011) Renal tumors and hereditary phaeochromocytoma-paraganglioma syndrome type 4. N Engl J Med 364:885–886CrossRefPubMed

Gill AJ, Hes O, Papathomas T et al (2014) Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity. A clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 38:1588–1602CrossRefPubMedPubMedCentral

Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15:55–64CrossRefPubMed

Haven CJ, Wong FK, van Dam EW et al (2000) A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 85:1449–1454PubMed

Hemminki K, Li X (2004) Familial renal cell cancer appears to have a recessive component. J Med Genet 41:e58CrossRefPubMedPubMedCentral

Henderson A, Douglas F, Perros P et al (2009) SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer 8:257–260CrossRefPubMed

Houweling AC, Gijezen LM, Jonker MA et al (2011) Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 105:1912–1919CrossRefPubMedPubMedCentral

Hu B, Lara PN Jr, Evans CP (2012) Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin N Am 39:233–249CrossRef

Jackson CE, Norum RA, Boyd SB et al (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108:1006–1013PubMed

Jafri M, Wake NC, Ascher DB et al (2015) Germline mutations in the CDKN2B tumor suppressor gene predispose to renal cell carcinoma. Cancer Discov 5:723–729CrossRefPubMed

Jonasch E, McCutcheon IE, Waguespack SG et al (2011) Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22:2661–2666CrossRefPubMedPubMedCentral

Krueger DA, Northrup H (2013) Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:255–265

Lachlan KL, Lucassen AM, Bunyan D et al (2007) Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 44:579–585CrossRefPubMedPubMedCentral

Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel-Lindau tumor suppressor gene. Science 260:1317–1320CrossRefPubMed

Lehtonen HJ (2011) Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer 10:397–411CrossRefPubMed

Leter EM, Koopmans AK, Gille JJP et al (2008) Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. J Invest Dermatol 128:45–49CrossRefPubMed

Li FP, Decker H-J, Zbar B et al (1993) Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma. Ann Intern Med 118:106–111

Lindau A (1926) Studien über Kleinhirncysten. Bau, Pathogenese und Beziehungen zur Angiomatosis retinae. Acta Pathol Microbiol Scand S1:1–128

Linehan WM (2012) Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 22:2089–2100CrossRefPubMedPubMedCentral

Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172CrossRefPubMed

Linehan WM, Srinivasan R, Schmidt LS (2010a) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7:277–285CrossRefPubMedPubMedCentral

Linehan WM, Bratslavsky G, Pinto PA et al (2010b) Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 61:329–343CrossRefPubMedPubMedCentral

Ljungberg B, Bensalah K, Bex A et al (2013) Guidelines: Renal cell carcinoma, European Association of Urology. www.uroweb.org

Lloyd KM II, Dennis M (1963) Cowden’s disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 58:136–142CrossRefPubMed

Lonser RR, Glenn GM, Walther M et al (2003) Von Hippel-Lindau disease. Lancet 361:2059–2067CrossRefPubMed

Maffé A, Toschi B, Circo G et al (2011) Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. Clin Genet 79:345–354CrossRefPubMed

Maher ER (2011) Genetics of familial renal cancers. Nephron Exp Nephrol 118:e21–e26CrossRefPubMed

Maher ER, Yates JRW, Harries R et al (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–1163CrossRefPubMed

Maher ER, Neumann HPH, Richard S (2011) Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 19:617–623

Malchoff CD, Sarfarazi M, Tendler B et al (2000) Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85:1758–1764PubMed

McKay L, Frydenberg M, Lipton L et al (2011) Case report: renal cell carcinoma segregating with a t(2;3)(q37.3;q13.2) chromosomal translocation in an Ashkenazi Jewish family. Fam Cancer 10:349–353CrossRefPubMed

Menko FH, van Steensel MAM, Giraud S et al (2009) Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 10:1199–1206CrossRefPubMed

Menko FH, Johannesma PC, van Moorselaar RJ et al (2013) A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. Fam Cancer 12:373–379CrossRefPubMed

Menko FH, Maher ER, Schmidt LS et al (2014) Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 13:637–644CrossRefPubMedPubMedCentral

Mester J, Eng C (2015) Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol 111:125–130CrossRefPubMed

Mester JL, Zhou M, Prescott N et al (2012) Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology 79:1187.e1–1187.e7

Metwalli AR, Linehan WM (2014) Nephron-sparing surgery for multifocal and hereditary tumors. Curr Opin Urol 24:466–473CrossRefPubMedPubMedCentral

Nahorski MS, Lim DHK, Martin L et al (2010) Investigation of the Birt-Hogg-Dubé tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet 47:385–390CrossRefPubMed

Ngeow J, Eng C (2015) PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol. Methods 77–78:11–19

Nickerson ML, Warren MB, Toro JR et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2:157–164CrossRefPubMed

Nieuwenhuis MH, Kets CM, Murphy-Ryan M et al (2014) Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer 13:57–63CrossRefPubMed

Northrup H, Krueger DA (2013) Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:243–254

Olivero M, Valente G, Bardelli A et al (1999) Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82:640–643CrossRefPubMed

Papathomas TG, Gaal J, Corssmit EPM et al (2014) Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 170:1–12

Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 26:1542–1552CrossRefPubMed

Popova T, Hebert L, Jacquemin V et al (2013) Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 92:974–980CrossRefPubMedPubMedCentral

Pressey JG, Wright JM, Geller JI et al (2010) Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer 54:1035–1037PubMed

Qin Y, Deng Y, Ricketts CJ et al (2014) The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet 23:2428–2439CrossRefPubMedPubMedCentral

Reaume MN, Graham GE, Tomiak E et al (2013) Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J 7:319–323CrossRefPubMedPubMedCentral

Reed WB, Walker R, Horowitz R (1973) Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 53:409–416PubMed

Richard S, Gardie B, Couvé S et al (2013) Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin Cancer Biol 23:26–37CrossRefPubMed

Ricketts C, Woodward ER, Killick P et al (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260–1262CrossRefPubMed

Ricketts CJ, Forman JR, Rattenberry E et al (2010) Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 31:41–51CrossRefPubMed

Ricketts CJ, Shuch B, Vocke CD et al (2012) Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 188:2063–2071CrossRefPubMed

Roma A, Maruzzo M, Basso U et al (2015) First-line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer 14:309–316CrossRefPubMed

Salvi A, Marchina E, Benetti A et al (2008) Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 33:271–276PubMed

Schmidt LS (2013) Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies. Fam Cancer 12:357–364 CrossRefPubMedPubMedCentral

Schmidt LS, Linehan WM (2014) Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis 7:253–260CrossRefPubMedPubMedCentral

Schmidt L, Duh F-M, Chen F et al (1997) Germline and somatic mutations in the thyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73CrossRefPubMed

Schmidt LS, Nickerson ML, Angeloni D et al (2004) Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the MET proto-oncogene. J Urol 172:1256–1261CrossRefPubMed

Shuch B, Ricketts CJ, Vocke CD et al (2013a) Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J Urol 189:430–435CrossRefPubMedPubMedCentral

Shuch B, Ricketts CJ, Vocke CD et al (2013b) Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol 190:1990–1998CrossRefPubMedPubMedCentral

Shuch B, Vourganti S, Ricketts CJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32:431–437CrossRefPubMedPubMedCentral

Shuch B, Amin A, Armstrong AJ et al (2015) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 67:85–97CrossRefPubMed

Smit DL, Mensenkamp AR, Badeloe S et al (2011) Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet 79:49–59CrossRefPubMed

Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489CrossRefPubMed

Stamatakis L, Metwalli AR, Middelton LA et al (2013) Diagnosis and management of BHD-associated kidney cancer. Fam Cancer 12:397–402CrossRefPubMedPubMedCentral

Sudarshan S, Karam JA, Brugarolas J et al (2013) Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol 63:244–251CrossRefPubMedPubMedCentral

Tan M-H, Mester JL, Ngeow J et al (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400–407CrossRefPubMedPubMedCentral

Teh BT, Farnebo F, Kristoffersson U et al (1996) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 81:4204–4211PubMed

Tollefson MK, Boorjian SA, Lohse CM et al (2010) The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int 106:1638–1642CrossRefPubMed

Tomlinson IPM, Alam NA, Rowan AJ et al (2002) The Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410CrossRefPubMed

Valle L, Cascón A, Melchor L et al (2005) About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t(3;8) (p14.1;q24.23) family. Eur J Hum Genet 13:570–578CrossRefPubMed

Van Nederveen FH, Gaal J, Favier J et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–771CrossRefPubMedPubMedCentral

Von Hippel E (1904) Ueber eine sehr seltene Erkrankung der Netzhaut. A von Graefe’s Arch Ophthalmol 59:83–106CrossRef

Wadt KAW, Gerdes A-M, Hansen TV et al (2012) Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Fam Cancer 11:535–537CrossRefPubMed

Wake NC, Ricketts CJ, Morris MR et al (2013) UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene. Hum Mutat 34:1650–1661CrossRefPubMedPubMedCentral

Woodward ER, Ricketts C, Killick P et al (2008) Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res 14:5925–5930CrossRefPubMed

Woodward ER, Skytte AB, Cruger DG et al (2010) Population-based survey of cancer risks in chromosome 3 translocation carriers. Genes Chromosomes Cancer 49:52–58CrossRefPubMed

Yang P, Cornejo KM, Sadow PM et al (2014) Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 38:895–909CrossRefPubMedPubMedCentral

Zbar B, Tory K, Merino M et al (1994) Hereditary papillary renal cell carcinoma. J Urol 151:561–566PubMed

Zbar B, Glenn G, Lubensky I et al (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912CrossRefPubMed

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Medicine Matters Oncology

Abstract